
The Truth About BPC-157 & Peptides (3 Doctors Discuss)
Episode 162
Social media decided the FDA just approved BPC-157, TB-500, and four other peptides. That's not what happened, and Dr. Leigh Baxt is the right person to explain why. Baxt is a translational scientist and drug development lead with training from Stanford, Harvard, and Brown. She walks Spencer and Karl through the actual language, which amounts to a double negative. These peptides were not added to the 503A bulks list and they did not become approved drugs. The FDA simply said it won't enforce the restriction on compounding pharmacies making them. Nothing was legalized. No rules changed. For context, only about five or six substances have been added to that list in 25 years, and nearly all of them were topical, not injectable. From there she lays out what real drug development looks like, and it's the clearest explanation of the process this show has run. Years of molecular work before an animal ever sees the compound. Preclinical toxicology and safety pharmacology designed specifically to prove you aren't causing harm. Chronic dosing studies, tumor growth, metastasis. Five or six years and millions of dollars just to earn permission to test in a human. Her number for how often it works: roughly 173 projects for one approved drug. She also dismantles the arguments you've probably heard. Patents aren't the reason pharma isn't developing these, because most of them are patented, and some companies let those patents lapse after walking away, which tells you something.
Publisher
Docs Who Lift
Link
podcasters.spotify.com/pod/show/docswholift
Published
November 3, 2026
Duration
29 min
Format
Podcast
Category
Lifestyle · Medicine
Source
RSS feed
Docs Who Lift
@docswholift
#peptides #doctorsdiscuss #medicine
